Home » U.S. Approves Spectrum Pharma’s Purchase of Allos
U.S. Approves Spectrum Pharma’s Purchase of Allos
U.S. antitrust officials have approved Spectrum Pharmaceuticals’ purchase of cancer drugmaker Allos Therapeutics, a $206 million deal aimed at giving Spectrum access to the Allos anti-cancer drug Folotyn.
Reuters
Reuters
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May